Cliquez ici pour écouter la traduction simultanée de cette diffusion
On-Demand Event

Breaking News from ATS.18

Original air date:
Wednesday, June 13, 2018

Running time: 1:03:42 minutes


Paul O’Byrne, MB, FRCP(C), FRSC (Program Chair)
Shannon Walker, MD, FRCPC
Paolo Renzi, MD, FCCP, FRCPC
Alan Kaplan, MD, CCFP(EM), FCFP

Scientific Planning Committee Members

Paul O’Byrne, MB, FRCP(C), FRSC (Program Chair)
Ronald Olivenstein, MD
Shannon Walker, MD, FRCPC
Paolo Renzi, MD, FCCP, FRCPC
Alan Kaplan, MD, CCFP(EM), FCFP

Get up-to-date information on the trials presented at the American Thoracic Society (ATS) Conference 2018 in San Diego, CA!

Language: English and French

Questions and Answers

Q&A Section title: Asthma Clinical Studies Update (0:00:00)

  • Do you feel there are certain asthma populations that would benefit to one strategy compared to the other? And how would you manage that in your practice? (0:00:02)
  • In SYGMA 2, adherence was quite high at 63%. In real life, if we did not have that amount of adherence with maintenance therapy, might we have seen more benefit of the “as-needed” anti-inflammatory reliever therapy? (0:01:10)
  • With the SYGMA results and other pragmatic studies coming up, do you anticipate a change in practice and guidelines? (0:02:10)
  • Why did you use well-controlled asthma weeks as your primary outcome? (0:03:18)
  • What would be the outcome on airway remodeling? (0:04:14)

Q&A Section title: ATS Highlight Session: Reports of Recently Published Pulmonary Research (0:04:56)

  • The adherence rate was very high with these children. Could that high adherence rate of maintenance therapy, even at low dose, have been of significance for these patients entering yellow zone? (0:05:00)
  • How does the magnitude of benefit of quadrupling or quintupling ICS dose compare to taking oral prednisone? Are we able to compare the safety of high dose inhaled corticosteroid versus short bursts of oral prednisone? (0:05:52)
  • Was there any impact on pneumonia? (0:07:03)
  • What do you think your patients in general practice are most concerned about when it comes to inhaled corticosteroids? (0:07:39)
  • How should we incorporate the results of these studies for the children and adults in our clinical practice, and what impact might these have on our national guidelines? (0:08:19)

Q&A Section title: What Else was Hot at ATS? (0:09:30)

  • Do you not fear that the message sent to clinicians and patients through these studies may lead to a shift in the regular treatment to treatments “as necessary" that may harm the overall management of asthma? (0:09:34)
  • Is there a role for use of SABA alone in patients with very mild asthma, or exercise-induced asthma given that the rat study might show increased remodeling? Or should we be using medications like Symbicort instead for their pre-exercise or prn for very mild asthma? (0:10:40)
  • For children that were in the quadrupling ICS that did show a delayed growth, is there any data that demonstrates children DO catch up because their asthma is being treated? (0:13:00)
  • If we are adding tiotropium or a LAMA to our ICS/LABA maintenance, is there a risk that patients may only take the LAMA and not the ICS? (0:14:01)
  • What is the current recommendation for exercise-induced asthma: Symbicort, a SABA or Ventolin? (0:15:02)


This Breaking News from ATS.18 activity meets the criteria of a Section 2 activity (Video) and is eligible for Section 2 credits under the Maintenance of Certification (MOC) Program.

Watch the Bonus Q&A Session (16 min)